Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection

Anita H. Nguyen, MD1, Babak Torabi Sagvand, MD2, Daniel G. Hwang, MD2, Teklu Legesse, MD3, and Raymond K. Cross, MD, MS, FACG, AGAF2

1Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
2Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
3Department of Pathology, University of Maryland School of Medicine, Baltimore, MD

ABSTRACT
Immune checkpoint inhibitors such as nivolumab increase the T-cell destruction of malignancies but can also trigger a broad variety of immune-related adverse events (irAEs). Colitis as an irAE is well-documented, but upper gastrointestinal tract involvement is primarily unrecognized. We present a patient who developed gastritis as an irAE after multiple cycles of nivolumab and initially responded well to steroid therapy but then developed superimposed cytomegalovirus infection. The similarity between both presentations highlights the importance of having a broad differential diagnosis in patients with gastrointestinal complaints treated with immune checkpoint inhibitors and the need for further studies to better characterize gastritis as an irAE.

INTRODUCTION
Programmed cell death protein 1, its ligand, and cytotoxic T-lymphocyte-associated antigen-4 are immune checkpoints that negatively regulate T-cell function. Immune checkpoint inhibitors (ICI) allow unregulated T-cell destruction of malignant cells and are used in a large number of cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, as well as gastric, colorectal, and hepatocellular carcinomas.1,2 However, immune-related adverse events (irAEs) have been reported in association with ICI.1,3 The most frequently affected organ systems are dermatologic, gastrointestinal (GI), hepatic, and endocrine, but all other systems have been involved.1 Lower GI involvement is common but the upper GI system is typically spared; esophagitis or gastritis without colitis is rarer still, and few cases from nivolumab specifically have been reported.4–10 Diagnosis can be challenging because irAEs can arise months after the initiation of therapy or even after cessation, but irAEs frequently improve with ICI discontinuation and corticosteroid administration.1,3,4

CASE REPORT
A 55-year-old man with a history of metastatic clear cell renal carcinoma developed progressive abdominal pain, nausea, and vomiting 7 months after starting nivolumab. Computed tomography at a local emergency department showed diffuse gastric inflammation. Subsequent esophagogastroduodenoscopy (EGD) showed severe mucosal erythema throughout the stomach. Biopsies from the body and antrum showed active chronic gastritis with erosions and were negative for metaplasia, dysplasia, malignancy, fungal elements, or Helicobacter pylori infection. He was given fluids and discharged on pantoprazole, famotidine, and sucralfate, but his symptoms progressed.

Three weeks later, the patient presented to our center with epigastric pain, nausea, hematemesis, melena, weight loss, and food intolerance. He denied diarrhea or hematochezia. He was hemodynamically stable but appeared ill, had epigastric tenderness, and...
was mildly anemic. Computed tomography showed diffuse gastric wall thickening. EGD revealed a diffuse severely erythematous and friable mucosa with mucosal sloughing in the entire examined stomach (Figure 1). The esophagus and duodenum were normal. Gastric biopsy showed infiltration of the lamina propria with inflammatory cells and erosive mucosa, suggestive of ICI-related gastritis (Figure 2). *Helicobacter pylori* and cytomegalovirus (CMV) immunostains were negative. Nivolumab was discontinued, and he was started on 2 mg/kg of methylprednisolone with rapid symptomatic improvement. He was discharged on the equivalent prednisone dose with plans for a slow taper but returned 2 weeks later with symptom recurrence.

Because he had been on steroids for 3 weeks, a dose of infliximab 5 mg/kg was administered for suspected steroid-refractory irAE. Repeat EGD showed diffuse severe inflammation characterized by adherent blood, erosions, erythema, friability, granularity, and confluent ulcerations in the entire stomach (Figure 3). Biopsies were notable for severe ulceration and granulation with CMV cytopathic changes, suggestive of superimposed CMV gastritis (Figure 4). Serum CMV polymerase chain reaction was positive at 3,457 IU/mL. Steroids were tapered over an additional week, whereas ganciclovir was initiated, resulting in progressive symptom improvement. The patient self-discontinued ganciclovir after 5 weeks when the planned EGD to confirm clearance was delayed. Three months after CMV diagnosis, EGD showed a diffuse moderately erythematous, granular, and friable mucosa with nodularity and contact oozing in the entire stomach. Biopsies showed an ulcerative gastric mucosa with dense organized granulation tissue and reactive changes, negative for CMV. Serum CMV polymerase chain reaction was also negative. At the 2-month follow-up, he reported near resolution of symptoms.

**DISCUSSION**

This case highlights the clinical manifestations and management of a patient with gastritis that occurred after nivolumab and was complicated by superimposed CMV infection. IrAEs can be challenging to recognize. “Classic” chemotherapies have well-characterized toxicities, widely known outside of oncology. By contrast, understanding the variety of organ systems affected and variable presentation of irAEs can be difficult. The variable delay between therapy initiation and symptom onset further complicates diagnosis. That our patient tolerated nivolumab treatment for more than 6 months before symptom onset is not unusual.

Our patient presented with gastritis, which was unexpected. Lower GI tract involvement is common in checkpoint blockade but upper tract, especially in isolation, seems to be exceedingly rare. Gonzalez et al described a case series including 37 cases of colitis with only 1 case of upper GI involvement in which the entire GI tract was affected. Only within the past few years have a handful of nivolumab-related gastritis cases been published. Kobayashi et al reported a case of gastritis...
after 4 months of nivolumab. Boike et al described a case of esophagitis and gastritis after nivolumab in a woman with preexisting lymphocytic colitis. Nishimura et al described a case of hemorrhagic gastritis related to nivolumab, ipilimumab, and infection with *Helicobacter pylori*. For our patient’s diagnosis, gross inflammation on endoscopy with marked inflammatory cell infiltration of the mucosa and glandular atrophy combined with the clinical history were crucial. Rapid symptom improvement with corticosteroids further supported irAE.

Development of superimposed CMV infection presented another diagnostic challenge because the patient experienced identical symptoms from a new, distinct etiology. Developing symptoms before tapering hinted at a different process because patients typically respond well to corticosteroids. However, steroid-resistant irAE do occur, which is why infliximab was attempted while awaiting CMV confirmation. The nivolumab drug label explicitly recommends considering CMV or other infectious etiologies in corticosteroid-refractory colitis. The difference in histopathologic appearance between nivolumab-related and CMV gastritis was essential: marked infiltration of lymphocytes and neutrophils in the mucosa negative for all infectious stains vs viral inclusions and immunohistochemical stain showing nuclear reactivity (Figures 2 and 4). The disrupted mucosa from irAE combined with prolonged steroid therapy likely predisposed the patient to CMV infection/ reactivation.

An array of side effects can occur from immune upregulation by checkpoint inhibitors, and the range of recognized effects continues to widen because the use of drug class increases. Further studies are needed to better characterize the incidence, natural history, and outcome of ICI-related gastritis and other rare irAEs. For almost any presentation in patients on ICIs, it is essential to maintain a broad differential that includes irAE, even if few cases have yet been documented. However, common etiologies, such as infection, in an immunocompromised patient should not be excluded, even if other etiologies had previously been identified.

**DISCLOSURES**

Author contributions: AH Nguyen and BT Sagvand wrote the article, revised the article for intellectual content, and approved the final article. T. Legesse provided the histology figures, revised the article for intellectual content, and approved the final article. DG Hwang revised the article for intellectual content and approved the final article. RK Cross revised the article for intellectual content, approved the final article, and is the article guarantor.
Financial disclosure: None to report.

Previous presentation: This case was presented at the American College of Gastroenterology Annual Scientific Meeting; October 23–28, 2020; Virtual.

Informed consent was obtained for this case report.

Received January 25, 2021; Accepted November 9, 2021

REFERENCES

1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

2. Bristol-Myers Squibb Pharmaceutical Company. Opdivo (Nivolumab) [package Insert]. U.S. Food and Drug Administration website (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s075lbl.pdf) (2019). Accessed May 21, 2020.

3. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol. 2016;2(10):1346–53.

4. Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7(1):165.

5. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: Case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology. 2017;70(4):558–67.

6. Kobayashi M, Yamaguchi O, Nagata K, Nonaka K, Ryozawa S. Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc. 2017;86(5):915–6.

7. Boike J, DeJuliio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J 2017;4:e57.

8. Nishimura Y, Yasuda M, Ocho K, et al. Severe gastritis after administration of nivolumab and ipilimumab. Case Rep Oncol. 2018;11(2):549–56.

9. Lu J, Firpi-Morell RJ, Dang LH, Lai J, Liu X. An unusual case of gastritis in one patient receiving PD-1 blocking therapy: Coexisting immune-related gastritis and cytomegaloviral infection. Gastroenterol Res. 2018;11(5):383–7.

10. Sharma A, Faulx A, Blum A. Severe CMV gastritis associated with pembrolizumab therapy. Am J Gastroenterol. 2018;113:S1486–S1487.

11. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68.

12. Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis: What to do and when? Best Pract Res Clin Gastroenterol. 2020;48101703–49.

Copyright: © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.